Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Ogast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 125Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amarin Emphasizes Icosapent Ethyl's Role In Cardiovascular Risk
    Amarin Emphasizes Icosapent Ethyl's Role In Cardiovascular Risk

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258171/18362/en/Amarin-Highlights-Guideline-Recommended-Role-of-Icosapent-Ethyl-in-Managing-Cardiovascular-Risk-Following-Release-of-Updated-2026-ACC-AHA-Multisociety-Dyslipidemia-Guideline.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    REDUCE-IT Data on EPA Effects to Be Presented at ACC Expo
    REDUCE-IT Data on EPA Effects to Be Presented at ACC Expo

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256251/18362/en/New-REDUCE-IT-Data-in-Patients-at-Extreme-Cardiovascular-Risk-and-In-Vitro-Research-on-the-Mechanistic-Effects-of-Eicosapentaenoic-Acid-EPA-on-Lipoprotein-a-Lp-a-Oxidation-to-be-Pr.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Icosapent Ethyl Reduces Hospitalization And Death Risk
    Icosapent Ethyl Reduces Hospitalization And Death Risk

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247357/18362/en/Effects-of-Icosapent-Ethyl-on-Risk-and-Duration-of-Hospitalizations-and-Death-in-REDUCE-IT-Post-Hoc-Analysis-Published-in-the-European-Journal-of-Preventive-Cardiology.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case

    27 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/scotus-weighs-skinny-labels-top-us-lawyer-calls-toss-amarin-case-over-hikmas-vascepa-generic

    FIERCE PHARMA
    27 Feb 2026
    Share Share
    Amarin Unveils 2025 Q4 And Full-Year Financials
    Amarin Unveils 2025 Q4 And Full-Year Financials

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244479/18362/en/Amarin-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Amarin Spotlights Underused CVD Therapies for American Heart
    Amarin Spotlights Underused CVD Therapies for American Heart

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242553/18362/en/This-American-Heart-Month-Amarin-Spotlights-the-Need-to-Prioritize-Proven-Widely-Available-Yet-Underutilized-Therapies-in-the-Battle-Against-Cardiovascular-Disease.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.